Meningococcal serogroup Y disease in Europe: Continuation of high importance in some European regions in 2013

被引:51
作者
Broeker, Michael [1 ]
Emonet, Stephane [2 ]
Fazio, Cecilia [3 ]
Jacobsson, Susanne [4 ]
Koliou, Maria [5 ]
Kuusi, Markku [6 ]
Pace, David [7 ]
Paragi, Metka [8 ]
Pysik, Alexander [1 ]
Simoes, Maria Joao [9 ]
Skoczynska, Anna [10 ]
Stefanelli, Paola [3 ]
Toropainen, Maija [6 ]
Taha, Muhamed-Kheir [11 ]
Tzanakaki, Georgina [12 ]
机构
[1] Novartis Vaccines & Diagnost GmbH, Marburg, Germany
[2] Hop Univ Geneves, Serv Malad Infect, Geneva, Switzerland
[3] Ist Super Sanita, Dept Infect Parasit & Immune Mediated Dis, I-00161 Rome, Italy
[4] Orebro Univ Hosp, Orebro, Sweden
[5] Minist Hlth, Unit Surveillance & Control Communicable Dis, Nikosia, Cyprus
[6] Natl Inst Hlth & Welf, Helsinki, Finland
[7] Mater Dei Hosp, Msida, Malta
[8] Natl Lab Hlth Environm & Foodstuffs, Dept Publ Hlth Microbiol, Ljubljana, Slovenia
[9] Inst Nacl Saude Dr Ricardo Jorge, Lisbon, Portugal
[10] Natl Reference Ctr Bacterial Meningitis, Natl Med Inst, Warsaw, Poland
[11] Inst Pasteur, Paris, France
[12] Natl Sch Publ Hlth, Athens, Greece
关键词
epidemiology; Europe; invasive meningococcal disease; meningococcal serogroup Y; Neisseria meningitidis; IMD; Invasive meningococcal disease; Men; meningococcal; ADOLESCENTS; TRENDS;
D O I
10.1080/21645515.2015.1051276
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 ; 0836 ; 090102 ; 100705 ;
摘要
Neisseria meningitidis or meningococcus is divided into 12 distinct serogroups of which A, B, C, W, X, and Y are medically most important and cause health problems in different parts of the world. The epidemiology of N. meningitidis is unpredictable over time and across geographic regions. Globally, serogoup A has been prevalent in the African meningitis belt whereas serogroup B and C have predominated in Europe. In a paper published earlier in this journal(1), an increase in serogroup Y invasive meningococcal disease (IMD) in some European countries was reported based on the epidemiological data for 2010, 2011 and 2012. Here, we report additional data from 30 European countries indicating that high or increased serogroup Y disease levels have continued in 2013 in certain regions of Europe. In the Western and Central Europe, there were no major changes in the proportion of serogroup Y IMD cases in 2013 compared to 2012. In the Scandinavian countries, proportion of serogroup Y disease remained high, ranging from 26% to 51% in 2013. This was in contrast to Baltic, Eastern and most Southern European countries, where the proportion of serogroup Y IMD was low similarly to previous years. For the last 2 decades, the mean age of patients affected by serogroup Y was 41 y for 7 countries from which data was available and 50% of cases were in patients aged 45 to 88 y. The age distribution of serogroup Y was bimodal and did not change significantly despite the increase of the total number and the proportion of serogroup Y IMD in some European regions.
引用
收藏
页码:2281 / 2286
页数:6
相关论文
共 22 条
  • [1] Meningococcal serogroup Y emergence in Europe High importance in some European regions in 2012
    Broeker, Michael
    Bukovski, Suzana
    Culic, Davor
    Jacobsson, Susanne
    Koliou, Maria
    Kuusi, Markku
    Simoes, Maria Joao
    Skoczynska, Anna
    Toropainen, Maija
    Taha, Muhamed-Keir
    Tzanakaki, Georgina
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (06) : 1725 - 1728
  • [2] Meningococcal serogroup Y emergence in Europe Update 2011
    Broeker, Michael
    Jacobsson, Susanne
    Kuusi, Markku
    Pace, David
    Simoes, Maria J.
    Skoczynska, Anna
    Taha, Muhamed-Kheir
    Toropainen, Maija
    Tzanakaki, Georgina
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (12) : 1907 - 1911
  • [3] Clinical manifestations of invasive meningococcal disease in Victoria with the emergence of serogroup W and serogroup Y Neisseria meningitidis
    Birrell, Michael T.
    Strachan, Janet
    Holmes, Natasha E.
    Stevens, Kerrie
    Howden, Benjamin P.
    Franklin, Lucinda J.
    Ivan, Mihaela
    Kwong, Jason C.
    INTERNAL MEDICINE JOURNAL, 2021, 51 (03) : 390 - 397
  • [4] Increase of invasive meningococcal serogroup W disease in Europe, 2013 to 2017
    Krone, Manuel
    Gray, Steve
    Abad, Raquel
    Skoczynska, Anna
    Stefanelli, Paola
    van der Ende, Arie
    Tzanakaki, Georgina
    Molling, Paula
    Simoes, Maria Joao
    Krizova, Pavla
    Emonet, Stephane
    Caugant, Dominique A.
    Toropainen, Maija
    Vazquez, Julio
    Borrow, Ray
    Wasko, Izabela
    Knol, Miriam J.
    Jacobsson, Susanne
    Bettencourt, Celia Rodrigues
    Musilek, Martin
    Born, Rita
    Vogel, Ulrich
    EUROSURVEILLANCE, 2019, 24 (14): : 2 - 10
  • [5] Increase of meningococcal serogroup Y cases in Europe A reason for concern?
    Broeker, Michael
    Jacobsson, Susanne
    DeTora, Lisa
    Pace, David
    Taha, Muhamed-Kheir
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2012, 8 (05) : 685 - 688
  • [6] Global epidemiology of serogroup Y invasive meningococcal disease: a literature review
    Htar, Myint Tin Tin
    Findlow, Jamie
    Balmer, Paul
    Swerdlow, David
    EPIDEMIOLOGY & INFECTION, 2024, 152 : e157
  • [7] Epidemiology of serogroup C and Y invasive meningococcal disease (IMD) in Ontario, 2000-2013: Vaccine program impact assessment
    Wormsbecker, A. E.
    Wong, K.
    Jamieson, F. B.
    Crowcroft, N. S.
    Deeks, S. L.
    VACCINE, 2015, 33 (42) : 5678 - 5683
  • [8] Meningococcal disease due to serogroup Y in Scotland, 1992-1999
    Clarke, SC
    Reid, J
    Thom, L
    Denham, BC
    Edwards, GFS
    BRITISH JOURNAL OF BIOMEDICAL SCIENCE, 2001, 58 (01) : 17 - 19
  • [9] Increase in Meningococcal Serogroup W Disease, Victoria, Australia, 2013-2015
    Carville, Kylie S.
    Stevens, Kerrie
    Sohail, Asma
    Franklin, Lucinda J.
    Bond, Katherine A.
    Brahmi, Aicha
    Romanes, Finn
    Ong, Katherine S.
    EMERGING INFECTIOUS DISEASES, 2016, 22 (10) : 1785 - 1787
  • [10] Serogroup A, C, W, and Y meningococcal disease in persons previously vaccinated with a serogroup ACWY meningococcal vaccine-United States, 2014-2018
    Blain, Amy E.
    Reese, Heather E.
    Marjuki, Henju
    Topaz, Nadav
    Mbaeyi, Sarah
    McNamara, Lucy A.
    VACCINE, 2021, 39 (52) : 7541 - 7544